PT-141 (10mg)
Spécifications techniques
| Pureté (HPLC) | ≥99% (HPLC) |
| Numéro CAS | 189691-06-3 |
| Forme | White lyophilized powder |
| Stockage | -20°C |
| Séquence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Poids moléculaire | 1,025.21 g/mol |
| Forme saline | Acetate |
| Solubilité | Soluble in water |
PT-141 (10mg)
Prix catalogue EUR · HU, SK, CZ, PL
- Eurozone (EUR)182,70 EUR
- Hongrie (HU)182,70 EUR≈ 73 080 Ft
- Slovaquie (SK)182,70 EUR
- Tchéquie (CZ)182,70 EUR≈ 4 568 Kč
- Pologne (PL)182,70 EUR≈ 776,47 zł
Même prix catalogue en EUR pour livraison vers la Hongrie, la Slovaquie, la République tchèque et la Pologne. Paiement en EUR.
Montants HUF/CZK/PLN indicatifs convertis depuis l’EUR ; la Slovaquie utilise l’EUR. Taux approximatifs. Paiement en EUR.
Melanocortin receptor agonist for CNS research.
Mechanism: Agonist at MC3R/MC4R in hypothalamus, activates central arousal pathways.
Applications: Sexual function models, melanocortin studies, CNS pharmacology.
Note: FDA-approved as Vyleesi® for HSDD.
Strictement réservé à la recherche en laboratoire.
Non destiné à la consommation humaine, vétérinaire ou au diagnostic.
From the Peptide Explorer
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Key Mechanisms
- ›MC4R agonism (central, hypothalamic)
- ›MC3R partial agonism
- ›CNS-mediated arousal pathway
- ›Dopaminergic downstream signaling
- ›Independent of vascular mechanisms
Primary Research Areas
- ›Hypoactive sexual desire
- ›Melanocortin receptor pharmacology
- ›Central arousal pathways
- ›Female sexual dysfunction
Key Research Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Overview
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Origin: Derived from Melanotan II; developed by Palatin Technologies
Mechanism of Action
- MC4R agonism (central, hypothalamic)
- MC3R partial agonism
- CNS-mediated arousal pathway
- Dopaminergic downstream signaling
- Independent of vascular mechanisms
Primary Research Areas
- Hypoactive sexual desire
- Melanocortin receptor pharmacology
- Central arousal pathways
- Female sexual dysfunction
Key Published Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized, 2-8°C reconstituted
Important Notice
PT-141 (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Spécifications de recherche
Synthesized for strict analytical consistency. Verified via HPLC/MS.Voir les standards qualité →
Manipulation et stockage
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water